June 2016 Newsletter

June 15, 2016:

Double-Digit Refractive Growth Headlines Strong Q1-2016

Laser vision correction procedures increased 13.7 percent year over year.

June 15, 2016:

Valeant Losing Money on Walgreens Deal; Ophthalmic Drug Revenues Decline 30 Percent

New CEO may end deal, as he looks to move away from disruptive nine-month period.

June 15, 2016:

Saunders Outlines Allergan’s Plans for $40.5 Billion from Teva Deal

CEO said the funding will go toward buying back shares, paying down debt, and creating growth, which will include M&A deals.

June 15, 2016:

Otsuka Ends Development Deals with Acucela

The move followed news that Acucela’s emixustat missed its primary endpoint in a Phase IIb/III trial for GA.

June 15, 2016:

Clearside Biomedical Raises $50 Million in IPO

The biopharmaceutical company lowered the proposed deal size prior to launching the offering.

June 15, 2016:

Market Report: India’s US$1.4 Billion Ophthalmic Market Expected to Grow 6.5 Percent Annually

The country’s expanding economy is leading to increased government spending on eye care.

June 15, 2016:

Market Report: Rising Global Adoption of Phaco, FLACS to Fuel Cataract Equipment Market

Revenues are expected to total $1.6 billion in 2016.

June 15, 2016:

Orbis Unveils New Flying Eye Hospital on MD-10 Aircraft

The jet’s telemedicine platform will allow surgeons to continue mentoring students around the world after the plane has moved on, an Orbis official said.

June 15, 2016:

Robert Grant Leaves Role as CEO of Alphaeon

The company founder said in 2015 that about 500 doctors, including 200 ophthalmologists, had invested.

June 15, 2016:

Regeneron Takes Over Sponsorship of Science Talent Search with $100M Commitment

The drugmaker is only the third sponsor in 75 years of the nation's oldest high school science competition.

June 15, 2016:

June 2016 News Briefs

July 25, 2016:

New Report Highlights ‘Visual Health Crisis’ in China

Country faces myopia rate of more than 50 percent in four years, based on current trends.

Social media